NAS:ICLR (Ireland) Also trade in: UK

Icon PLC

$ 148.37 0 (0%)
Volume: 158,726 Avg Vol (1m): 268,670
Market Cap $: 8.01 Bil Enterprise Value $: 7.88 Bil
P/E (TTM): 24.32 P/B: 5.65
Earnings Power Value 67.32
Net Current Asset Value 4.72
Tangible Book 10.66
Projected FCF 83.24
Median P/S Value 95.65
Graham Number 38.25
Peter Lynch Value 123.95
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 7/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 1.37
Cash-To-Debt ranked lower than
66.28% of 261 companies
in the Diagnostics & Research industry.
Industry Max: 32990, Med: 3.52, Min: 0.01
ICLR: 1.37
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.55, Med: 9.94, Max: 10000
Current: 1.37
0.55
10000
Equity-to-Asset 0.55
Equity-to-Asset ranked lower than
59.00% of 239 companies
in the Diagnostics & Research industry.
Industry Max: 0.97, Med: 0.61, Min: -2.81
ICLR: 0.55
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.44, Med: 0.63, Max: 0.77
Current: 0.55
0.44
0.77
Debt-to-Equity 0.25
Debt-to-Equity ranked higher than
56.10% of 164 companies
in the Diagnostics & Research industry.
Industry Max: 22.86, Med: 0.36, Min: 0.01
ICLR: 0.25
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0, Med: 0.11, Max: 0.46
Current: 0.25
0
0.46
Debt-to-EBITDA 0.77
Debt-to-EBITDA ranked higher than
66.38% of 116 companies
in the Diagnostics & Research industry.
Industry Max: 77.72, Med: 1.77, Min: 0.03
ICLR: 0.77
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: 0.77, Med: 0.9, Max: 1.02
Current: 0.77
0.77
1.02
Interest Coverage 30.32
Interest Coverage ranked lower than
57.06% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 15605.52, Med: 76.01, Min: 0.54
ICLR: 30.32
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 23.91, Med: 34.14, Max: 268.98
Current: 30.32
23.91
268.98
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 6.41
DISTRESS
GREY
SAFE
Beneish M-Score -2.11
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 28.5%
WACC 4.28%

Profitability & Growth : 8/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 14.94
Operating Margin ranked higher than
88.84% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 53.36, Med: -0.59, Min: -70300
ICLR: 14.94
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: 4.15, Med: 13.08, Max: 19.68
Current: 14.94
4.15
19.68
Net Margin % 12.56
Net Margin ranked higher than
90.87% of 241 companies
in the Diagnostics & Research industry.
Industry Max: 41.13, Med: -2.48, Min: -119600
ICLR: 12.56
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: 2.42, Med: 11.05, Max: 16.01
Current: 12.56
2.42
16.01
ROE % 25.39
ROE ranked higher than
94.21% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 61.7, Med: -6.75, Min: -12038.19
ICLR: 25.39
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: 3.39, Med: 18.44, Max: 30.7
Current: 25.39
3.39
30.7
ROA % 14.25
ROA ranked higher than
90.46% of 262 companies
in the Diagnostics & Research industry.
Industry Max: 1174.65, Med: -4.54, Min: -1248.4
ICLR: 14.25
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: 2.31, Med: 11.12, Max: 14.8
Current: 14.25
2.31
14.8
ROC (Joel Greenblatt) % 248.24
ROC (Joel Greenblatt) ranked higher than
92.66% of 259 companies
in the Diagnostics & Research industry.
Industry Max: 17601.65, Med: -9.57, Min: -3842027.78
ICLR: 248.24
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: 13.96, Med: 97.64, Max: 248.24
Current: 248.24
13.96
248.24
3-Year Total Revenue Growth Rate 18.10
3-Year Revenue Growth Rate ranked higher than
63.19% of 182 companies
in the Diagnostics & Research industry.
Industry Max: 371, Med: 4.8, Min: -100
ICLR: 21.9
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -14.6, Med: 11.75, Max: 54.3
Current: 21.9
-14.6
54.3
3-Year Total EBITDA Growth Rate 9.30
3-Year EBITDA Growth Rate ranked higher than
69.66% of 178 companies
in the Diagnostics & Research industry.
Industry Max: 141.7, Med: 10.1, Min: -340.1
ICLR: 12.8
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -20.2, Med: 6.65, Max: 52.9
Current: 12.8
-20.2
52.9
3-Year EPS w/o NRI Growth Rate 14.10
3-Year EPS w/o NRI Growth Rate ranked higher than
69.94% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 138.7, Med: 10.1, Min: -301
ICLR: 14.1
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -34.2, Med: 12.35, Max: 94.7
Current: 14.1
-34.2
94.7

» ICLR's 30-Y Financials

Financials (Next Earnings Date: 2019-07-26)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:ICLR

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Diagnostics & Research    NAICS : 621511    SIC : 8099
Compare XPAR:ERF NAS:GH NAS:BRKR NYSE:QGEN NYSE:BIO NYSE:CRL MIL:DIA NAS:PRAH NYSE:PKI XPAR:BIM NAS:SYNH NAS:DXCM SHSE:603658 SZSE:300676 XTER:SRT NAS:NEOG NAS:EXAS BSP:DASA3 NAS:QDEL SHSE:603882
Traded in other countries 0NBW.UK
Address South County Business Park, Leopardstown, Dublin, IRL, 18
Icon is a global late-stage contract research organization that provides drug development and clinical testing services to pharmaceutical, biotechnology, and medical device companies. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities.

Ratios

Current vs industry vs history
PE Ratio (TTM) 24.32
PE Ratio ranked higher than
69.03% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35, Min: 0.33
ICLR: 24.32
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 9.92, Med: 21.47, Max: 78.03
Current: 24.32
9.92
78.03
Forward PE Ratio 21.55
Forward P/E ranked higher than
67.50% of 40 companies
in the Diagnostics & Research industry.
Industry Max: 78.74, Med: 9999, Min: 11.64
ICLR: 21.55
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 24.32
PE without NRI ranked higher than
69.91% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35.56, Min: 0.34
ICLR: 24.32
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 9.92, Med: 21.47, Max: 78.03
Current: 24.32
9.92
78.03
Price-to-Owner-Earnings 32.45
Price-to-Owner-Earnings ranked higher than
75.00% of 76 companies
in the Diagnostics & Research industry.
Industry Max: 1523.53, Med: 36.75, Min: 4.91
ICLR: 32.45
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 6.23, Med: 24.35, Max: 103.98
Current: 32.45
6.23
103.98
PB Ratio 5.65
PB Ratio ranked lower than
60.41% of 245 companies
in the Diagnostics & Research industry.
Industry Max: 270, Med: 4.02, Min: 0.15
ICLR: 5.65
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 1.34, Med: 2.96, Max: 6.53
Current: 5.65
1.34
6.53
PS Ratio 3.06
PS Ratio ranked higher than
50.00% of 230 companies
in the Diagnostics & Research industry.
Industry Max: 6350, Med: 3.81, Min: 0.07
ICLR: 3.06
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.87, Med: 1.97, Max: 3.91
Current: 3.06
0.87
3.91
Price-to-Free-Cash-Flow 29.38
Price-to-Free-Cash-Flow ranked higher than
67.50% of 80 companies
in the Diagnostics & Research industry.
Industry Max: 1356.19, Med: 29.22, Min: 0.35
ICLR: 29.38
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 5.85, Med: 20.73, Max: 41.42
Current: 29.38
5.85
41.42
Price-to-Operating-Cash-Flow 25.09
Price-to-Operating-Cash-Flow ranked higher than
62.89% of 97 companies
in the Diagnostics & Research industry.
Industry Max: 1739.7, Med: 19.94, Min: 0.35
ICLR: 25.09
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 5.07, Med: 16.32, Max: 86.1
Current: 25.09
5.07
86.1
EV-to-EBIT 20.24
EV-to-EBIT ranked higher than
67.80% of 118 companies
in the Diagnostics & Research industry.
Industry Max: 341.21, Med: 25.06, Min: 5.74
ICLR: 20.24
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -10.1, Med: 17.1, Max: 48
Current: 20.24
-10.1
48
EV-to-EBITDA 17.37
EV-to-EBITDA ranked higher than
63.64% of 132 companies
in the Diagnostics & Research industry.
Industry Max: 486.47, Med: 20.75, Min: 3.94
ICLR: 17.37
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -11.3, Med: 13.1, Max: 19.5
Current: 17.37
-11.3
19.5
EV-to-Revenue 2.97
EV-to-Revenue ranked higher than
53.72% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 19679, Med: 4.24, Min: 0.09
ICLR: 2.97
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 0.8, Med: 1.9, Max: 3.9
Current: 2.97
0.8
3.9
PEG Ratio 1.03
PEG Ratio ranked higher than
93.75% of 48 companies
in the Diagnostics & Research industry.
Industry Max: 128.13, Med: 3.26, Min: 0.32
ICLR: 1.03
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 0.34, Med: 1.03, Max: 8.54
Current: 1.03
0.34
8.54
Shiller PE Ratio 47.11
Shiller PE Ratio ranked higher than
64.10% of 39 companies
in the Diagnostics & Research industry.
Industry Max: 459.08, Med: 52.49, Min: 10.19
ICLR: 47.11
Ranked among companies with meaningful Shiller PE Ratio only.
Shiller PE Ratio range over the past 10 years
Min: 11.77, Med: 31, Max: 53.99
Current: 47.11
11.77
53.99
Current Ratio 2.02
Current Ratio ranked lower than
62.00% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.58, Min: 0.02
ICLR: 2.02
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.12, Med: 1.95, Max: 3.61
Current: 2.02
1.12
3.61
Quick Ratio 2.02
Quick Ratio ranked lower than
55.20% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.14, Min: 0.02
ICLR: 2.02
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.12, Med: 1.95, Max: 3.61
Current: 2.02
1.12
3.61
Days Sales Outstanding 58.39
Days Sales Outstanding ranked lower than
63.24% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 521.64, Med: 67.51, Min: 1
ICLR: 58.39
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 58.33, Med: 84.5, Max: 94.82
Current: 58.39
58.33
94.82
Days Payable 3.78
Days Payable ranked higher than
74.87% of 187 companies
in the Diagnostics & Research industry.
Industry Max: 981.81, Med: 63.34, Min: 1
ICLR: 3.78
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 1.98, Med: 15.08, Max: 130.79
Current: 3.78
1.98
130.79

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate 0.10
3-Year Share Buyback Rate ranked higher than
99.44% of 180 companies
in the Diagnostics & Research industry.
Industry Max: 3.4, Med: -7.9, Min: -1732.6
ICLR: 0.1
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -61.5, Med: -0.8, Max: 16.4
Current: 0.1
-61.5
16.4

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 13.92
Price-to-Tangible-Book ranked lower than
86.96% of 207 companies
in the Diagnostics & Research industry.
Industry Max: 272.36, Med: 6.46, Min: 0.21
ICLR: 13.92
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 0.64, Med: 3.91, Max: 39.34
Current: 13.92
0.64
39.34
Price-to-Projected-FCF 1.78
Price-to-Intrinsic-Value-Projected-FCF ranked higher than
65.33% of 75 companies
in the Diagnostics & Research industry.
Industry Max: 449, Med: 2.41, Min: 0.47
ICLR: 1.78
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.51, Med: 1.65, Max: 6.7
Current: 1.78
0.51
6.7
Price-to-Median-PS-Value 1.56
Price-to-Median-PS-Value ranked lower than
87.05% of 193 companies
in the Diagnostics & Research industry.
Industry Max: 7.22, Med: 1.01, Min: 0.01
ICLR: 1.56
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.29, Med: 0.75, Max: 1.82
Current: 1.56
0.29
1.82
Price-to-Peter-Lynch-Fair-Value 1.19
Price-to-Peter-Lynch-Fair-Value ranked higher than
93.33% of 30 companies
in the Diagnostics & Research industry.
Industry Max: 15.31, Med: 2.01, Min: 0.83
ICLR: 1.19
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 0.2, Med: 0.97, Max: 3.26
Current: 1.19
0.2
3.26
Price-to-Graham-Number 3.88
Price-to-Graham-Number ranked lower than
61.84% of 76 companies
in the Diagnostics & Research industry.
Industry Max: 49.42, Med: 3.98, Min: 0.39
ICLR: 3.88
Ranked among companies with meaningful Price-to-Graham-Number only.
Price-to-Graham-Number range over the past 10 years
Min: 0.51, Med: 1.81, Max: 5.84
Current: 3.88
0.51
5.84
Earnings Yield (Joel Greenblatt) % 4.94
Earnings Yield (Greenblatt) ranked higher than
85.66% of 265 companies
in the Diagnostics & Research industry.
Industry Max: 17.42, Med: -0.98, Min: -1428.57
ICLR: 4.94
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -25.2, Med: 5.8, Max: 11.8
Current: 4.94
-25.2
11.8
Forward Rate of Return (Yacktman) % 22.79
Forward Rate of Return ranked higher than
94.29% of 70 companies
in the Diagnostics & Research industry.
Industry Max: 7802.99, Med: 8.45, Min: -35.9
ICLR: 22.79
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: -15, Med: 14.4, Max: 24.2
Current: 22.79
-15
24.2

More Statistics

Revenue (TTM) (Mil) $ 2,650.5
EPS (TTM) $ 6.1
Beta 0.65
Volatility % 21.18
52-Week Range $ 118.1 - 155.33
Shares Outstanding (Mil) 53.97

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA N
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy Y
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y